JP2025072482A5 - - Google Patents

Info

Publication number
JP2025072482A5
JP2025072482A5 JP2025016649A JP2025016649A JP2025072482A5 JP 2025072482 A5 JP2025072482 A5 JP 2025072482A5 JP 2025016649 A JP2025016649 A JP 2025016649A JP 2025016649 A JP2025016649 A JP 2025016649A JP 2025072482 A5 JP2025072482 A5 JP 2025072482A5
Authority
JP
Japan
Prior art keywords
poxvirus
nucleic acid
cancer
chimeric poxvirus
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025016649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025072482A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/046163 external-priority patent/WO2018031694A1/en
Application filed filed Critical
Publication of JP2025072482A publication Critical patent/JP2025072482A/ja
Publication of JP2025072482A5 publication Critical patent/JP2025072482A5/ja
Pending legal-status Critical Current

Links

JP2025016649A 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用 Pending JP2025072482A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662372408P 2016-08-09 2016-08-09
US62/372,408 2016-08-09
US201762519010P 2017-06-13 2017-06-13
US62/519,010 2017-06-13
PCT/US2017/046163 WO2018031694A1 (en) 2016-08-09 2017-08-09 Chimeric poxvirus compositions and uses thereof
JP2019507161A JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用
JP2022017693A JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023200433A Division JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2025072482A JP2025072482A (ja) 2025-05-09
JP2025072482A5 true JP2025072482A5 (cg-RX-API-DMAC7.html) 2025-09-09

Family

ID=61163330

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019507161A Active JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用
JP2022017693A Active JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A Pending JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2019507161A Active JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用
JP2022017693A Active JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用

Country Status (10)

Country Link
US (2) US12084687B2 (cg-RX-API-DMAC7.html)
EP (1) EP3497209A4 (cg-RX-API-DMAC7.html)
JP (4) JP7023929B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250067190A (cg-RX-API-DMAC7.html)
CN (3) CN118834840A (cg-RX-API-DMAC7.html)
AU (3) AU2017311380A1 (cg-RX-API-DMAC7.html)
CA (1) CA3033512A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019001672A (cg-RX-API-DMAC7.html)
RU (2) RU2021128158A (cg-RX-API-DMAC7.html)
WO (1) WO2018031694A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
WO2017147554A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
KR20250067190A (ko) * 2016-08-09 2025-05-14 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
CN111163803B (zh) 2017-08-11 2025-05-09 希望之城公司 表达car t细胞靶物的溶瘤病毒及其用途
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Car t細胞療法のための配列決定法
CA3093093A1 (en) * 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2019213173A1 (en) * 2018-04-30 2019-11-07 City Of Hope Neural stem cell compositions including chimeric poxviruses for cancer treatment
CA3112654A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
WO2023213763A1 (en) * 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스
WO2024245722A2 (en) * 2023-05-26 2024-12-05 Probiogen Ag Rapid selection system for the generation of recombinant enveloped viruses
US12698512B2 (en) 2023-11-06 2026-08-04 City Of Hope Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
WO2026107113A1 (en) 2024-11-12 2026-05-21 Calidi Biotherapeutics (Nevada), Inc. MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF
CN120718864B (zh) * 2025-08-28 2025-11-28 山东农业大学 一种高度不成熟鸭坦布苏病毒及其培养方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406376B (de) 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
JP2003528605A (ja) 2000-03-28 2003-09-30 ユニヴァーシティー オヴ ロチェスター ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
ATE365220T1 (de) * 2002-11-25 2007-07-15 Bavarian Nordic As Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
MXPA05013879A (es) * 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
EP2415783B1 (en) * 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
EP2212423B1 (en) * 2007-11-19 2015-02-11 Transgene SA Poxviral oncolytic vectors
JP5652830B2 (ja) 2010-04-09 2015-01-14 国立大学法人 東京大学 マイクロrna制御組換えワクシニアウイルス及びその使用
EP2697368B1 (en) 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
NZ701949A (en) * 2012-05-18 2016-07-29 Otago Innovation Ltd Combination treatments and compositions for wound healing
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR20250067190A (ko) * 2016-08-09 2025-05-14 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2024026191A5 (cg-RX-API-DMAC7.html)
RU2019106319A (ru) Композиции химерного поксвируса и их применение
JP2022065034A5 (cg-RX-API-DMAC7.html)
JP2019524131A5 (cg-RX-API-DMAC7.html)
CN101868474B (zh) 痘病毒溶瘤载体
CN101868546B (zh) 痘病毒溶瘤载体
Zhang et al. The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14. 5L inactivation
KR20170018450A (ko) 세포 치료제로서의 car-발현 nk-92 세포
AU2024200997A1 (en) Synthetic chimeric poxviruses
Brunetti et al. Complete Genomic Sequence and Comparative Analysis ofthe Tumorigenic Poxvirus Yaba Monkey TumorVirus
JP2021106576A (ja) 変異体腫瘍溶解性ワクシニアウイルスおよびその使用法
CN119530301B (zh) 一种治疗癌症的慢病毒及其制备方法和应用
WO2020011754A1 (en) Chimeric vaccinia viruses
JP6657115B2 (ja) ポックスウイルス腫瘍細胞崩壊性ベクター
Shchelkunov et al. Two types of deletions in orthopoxvirus genomes
EP2680867B1 (en) Enhanced tumor therapy by tumor stem cell targeted oncolytic viruses
CN107164337B (zh) 含ccl5和sstr2基因的重组痘病毒及其制备方法
EP3132038A1 (en) Adenoviral targeting, compositions and methods therefor
TW202014200A (zh) 包含合成嵌合牛痘病毒之幹細胞及其使用方法
US20230340424A1 (en) Mutant orf viruses and uses thereof
WO2018067165A1 (en) Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
KR100635447B1 (ko) 종양 특이적 자살유전자 발현 카세트 및 이를 포함하는아데노바이러스 발현 벡터
WO2020212500A1 (en) Oncolytic adenoviral vector expressing granzyme and perforin
Vasić Molecular targets and gene therapy of lung cancer.
BR112019008781B1 (pt) Vírus quimérico sintético da varíola equina (schpxv) ou vírus vaccinia quimérico sintético (scvacv), seu método de produção, seus usos e composição